Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ: TEM )

58.60 +6.12 (+11.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tempus AI, Inc. - Class A Common Stock

Artificial Intelligence (AI) Reshaping Healthcare Industry with Unimaginable Potential
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:TDOC),(NASDAQ:TEM),(NYSE:MDT),(NASDAQ:CLOV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Fraud
Exposures Artificial Intelligence Legal
How AI is Shaping the Future of Healthcare: Key Advances in Diagnostics and Precision Medicine
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:BFLY),(NASDAQ:TEM),(NASDAQ:GEHC),(NASDAQ:RDNT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Artificial Intelligence (AI) Reshaping Healthcare Industry with Unimaginable Potential
From FN Media Group LLC
Via GlobeNewswire
Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®
From Tempus AI, Inc.
Via Business Wire
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
From Tempus AI, Inc.
Via Business Wire
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
From Tempus AI, Inc.
Via Business Wire
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
From Tempus AI, Inc.
Via Business Wire
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
From Tempus AI, Inc.
Via Business Wire
Tempus to Report Third Quarter 2024 Financial Results on November 4
From Tempus AI, Inc.
Via Business Wire
Tempus to Report Third Quarter 2024 Financial Results on November 7
From Tempus AI, Inc.
Via Business Wire
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
From Tempus AI, Inc.
Via Business Wire
Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients
From Tempus AI, Inc.
Via Business Wire
Tempus Announces Real World Data Collaboration with BioNTech
From Tempus AI, Inc.
Via Business Wire
Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
MarketBeat Week in Review – 8/19 - 8/23
Stocks closed the week higher on the near certainty that the Fed will cut interest rates in September, but in the short term, all eyes are on NVDA earnings 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment
Tempus AI is a hot healthcare stock that investors should be aware of. It is using AI to pursue "precision medicine", especially in cancer research. 
Via MarketBeat
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay
From Tempus AI, Inc.
Via Business Wire
Tempus Reports Second Quarter 2024 Results
From Tempus AI, Inc.
Via Business Wire
Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2
From Tempus AI, Inc.
Via Business Wire
Tempus Announces Expanded Data and Sequencing Collaboration with Remix Therapeutics
From Tempus AI, Inc.
Via Business Wire
Tempus to Report Second Quarter 2024 Financial Results on August 6
From Tempus AI, Inc.
Via Business Wire
Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests
From Tempus AI, Inc.
Via Business Wire
Tempus Surpasses 500 Research Publications
From Tempus AI, Inc.
Via Business Wire
American Medical Association Grants PLA Code to Tempus Algorithmic Test, PurISTSM
From Tempus AI, Inc.
Via Business Wire
CMS Awards Tempus With Advanced Diagnostic Laboratory Test (ADLT) Status for its xT CDx Test
From Tempus AI, Inc.
Via Business Wire
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib
From Tempus
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.